Who are phenibut's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lioresal, Baclofen ER, placebo + oral baclofen, Xyrem, Low Sodium Oxybate, Sodium Oxybate (SMO).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/phenibut.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

phenibut — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

phenibut (phenibut) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

unknown GABA-B receptor Other Live · refreshed every 30 min

Target snapshot

phenibut (phenibut).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
phenibut TARGET	phenibut		unknown		GABA-B receptor
Lioresal	BACLOFEN		marketed	gamma-Aminobutyric Acid-ergic Agonist [EPC]	GABA-B receptor	1977-01-01
Baclofen ER	Baclofen ER	Alkermes, Inc.	marketed	GABA-B receptor agonist	GABA-B receptor
placebo + oral baclofen	placebo + oral baclofen	Shaare Zedek Medical Center	marketed	GABA-B receptor agonist	GABA-B receptor
Xyrem	Xyrem	Jazz Pharmaceuticals	marketed		Calcium/calmodulin-dependent protein kinase type II subunit alpha, GABA-B receptor, Gamma-hydroxybutyrate receptor
Low Sodium Oxybate	Low Sodium Oxybate	Leiden University Medical Center	marketed	GHB receptor agonist / GABA-B receptor agonist	GHB receptor, GABA-B receptor
Sodium Oxybate (SMO)	Sodium Oxybate (SMO)	Catholic University of the Sacred Heart	marketed	GABA-B receptor agonist; CNS depressant	GABA-B receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2037-09-08 — Lioresal · 11446246 · Method of Use · US
2037-09-29 — Lioresal · 11324696 · Formulation · US
2039-07-29 — Lioresal · 11654124 · Formulation · US
2039-07-29 — Lioresal · 10792262 · Formulation · US
2039-07-29 — Lioresal · 11931328 · Formulation · US
2039-08-30 — Lioresal · 10610502 · Method of Use · US
2041-09-29 — Lioresal · 11850225 · Formulation · US
2041-09-29 — Lioresal · 11491125 · Formulation · US

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). phenibut — Competitive Intelligence Brief. https://druglandscape.com/ci/phenibut. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing